Evolution Research Group and Invicro LLC Partner to Offer Clinical Research and Advanced Data Analysis and Management Services
NEW PROVIDENCE, N.J. & BOSTON--(BUSINESS WIRE)--Nov 18, 2019--
Today, Evolution Research Group (ERG) and Invicro LLC, a Konica Minolta Company announced a strategic partnership to offer biotech and pharma sponsors early to late phase clinical research trials, advanced data analysis and project management services.
ERG is a leading independent clinical research site company specializing in number of therapeutic areas including Psychiatry, Neurology, Alzheimer’s Disease, NASH, Diabetes and Tobacco among others. Invicro is a global provider of imaging biomarkers, core lab services, advanced analytics and software solutions for clinical research. This partnership will offer pharmaceutical sponsors a seamless process for inpatient and outpatient clinical research trials backed by unparallel support including centralized recruiting, operational excellence, clinical consultation, advanced data analysis and project management support.
“We are pleased to partner with such an industry leader in clinical research as ERG,” stated Mr. Roughan Sheedy, Chief Commercial Officer of Invicro. “We believe this alliance will allow our companies to jointly offer efficient and flexible clinical research studies that will deliver effective results to support our pharma sponsors’ drug development and clinical research projects.”
ERG has completed over 5,000 clinical trials leveraging a broad network of state-of-the-art ERG portfolio and affiliate sites throughout the United States, supporting both early and late-phase clinical trials. Invicro has processed nearly 25-million (DICOM) images and defined over 6-million unique quantification data points. The combined strength of ERG and Invicro, will allow pharma and biotech customers to uncover answers to support more timely and accurate decision-making throughout their clinical research trials.
“Invicro’s innovation and expertise in the area of medical imaging biomarkers, advanced analytics and software is unprecedented,” noted Dr. Davide Molho, President and CEO of ERG. “We look forward to this collaboration to support the research community and their life-changing research projects across all therapeutic areas.”
The partnership between ERG and Invicro is effective immediately.
About Evolution Research Group
ERG is one of the largest, independent, wholly owned research site organizations in the country, with a leading position in the CNS clinical trials industry. Evolution Research Group, LLC comprises 13 wholly owned and operated clinical research units, and an established network of affiliated clinical research sites. ERG conducts a wide range of simple and highly complex trials in specialized populations, including those suffering from psychiatric and neurological disorders, sleep disorders, addictions, acute and chronic pain, renal insufficiency, hepatic impairment, as well as normal healthy volunteers.
The ERG team, which consists of over 400 employees, owns and operates specialty inpatient and outpatient research units across the country, conducting phase I-IV clinical research trials. Additionally, ERG manages a network of affiliated clinical research sites and has access to over 32 million potential patients to support sponsors conducting research.
Learn more about ERG by visiting www.ergclinical.com
Headquartered in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Today, Invicro’s multi-disciplinary team provides solutions to pharmaceutical and biotech companies across all stages of the drug development pipeline (Phase 0-IV), all imaging modalities and all therapeutic areas, including neurology, oncology, cardiology, and pulmonary. Invicro’s quantitative biomarker services, advanced analytics and AI tools, and clinical operational services are backed by Invicro’s industry-leading software informatics platforms, VivoQuant® and iPACS®.
As part of the Konica Minolta precision medicine organization and with their sister company Ambry Genetics, Invicro develops and leverages the latest approaches in quantitative biomarkers including imaging, quantitative pathology and genomics. For more information, visit www.invicro.com.
About Konica Minolta
Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and society—today and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customer’s most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrow’s issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191118005523/en/
CONTACT: Amanda Harrell
VP, Global Marketing
KEYWORD: MASSACHUSETTS NEW JERSEY UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH OTHER HEALTH OTHER SCIENCE RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Invicro LLC
Copyright Business Wire 2019.
PUB: 11/18/2019 09:51 AM/DISC: 11/18/2019 09:51 AM